As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
Teva is currently involved in patent litigation concerning this product in the US District Court of Delaware. A trial date has not been set.